TW202241881A - Cdk抑制劑之共晶體 - Google Patents

Cdk抑制劑之共晶體 Download PDF

Info

Publication number
TW202241881A
TW202241881A TW110147455A TW110147455A TW202241881A TW 202241881 A TW202241881 A TW 202241881A TW 110147455 A TW110147455 A TW 110147455A TW 110147455 A TW110147455 A TW 110147455A TW 202241881 A TW202241881 A TW 202241881A
Authority
TW
Taiwan
Prior art keywords
compound
formula
fumarate
crystal
mixture
Prior art date
Application number
TW110147455A
Other languages
English (en)
Chinese (zh)
Inventor
尤戴 巴特
羅納迪普 巴卡利亞
桑格麥許 埃許韋瑞帕 貝笛格
克力許納斯瓦米 德衛納森
Original Assignee
印度商阿瑞吉探索科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 印度商阿瑞吉探索科技股份有限公司 filed Critical 印度商阿瑞吉探索科技股份有限公司
Publication of TW202241881A publication Critical patent/TW202241881A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110147455A 2020-12-18 2021-12-17 Cdk抑制劑之共晶體 TW202241881A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18

Publications (1)

Publication Number Publication Date
TW202241881A true TW202241881A (zh) 2022-11-01

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110147455A TW202241881A (zh) 2020-12-18 2021-12-17 Cdk抑制劑之共晶體

Country Status (17)

Country Link
US (1) US20240059669A1 (https=)
EP (1) EP4263534A1 (https=)
JP (1) JP2023554492A (https=)
KR (1) KR20230159363A (https=)
CN (1) CN116685326A (https=)
AU (1) AU2021402415A1 (https=)
CA (1) CA3202198A1 (https=)
CL (1) CL2023001753A1 (https=)
CO (1) CO2023009368A2 (https=)
CR (1) CR20230261A (https=)
DO (1) DOP2023000126A (https=)
EC (1) ECSP23054131A (https=)
IL (1) IL303738A (https=)
MX (1) MX2023007218A (https=)
PE (1) PE20231441A1 (https=)
TW (1) TW202241881A (https=)
WO (1) WO2022130304A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022084930A2 (en) * 2020-10-22 2022-04-28 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3302448T1 (sl) 2015-06-04 2024-03-29 Aurigene Oncology Limited Substituirani heterociklični derivati kot inhibitorji cdk

Also Published As

Publication number Publication date
CO2023009368A2 (es) 2023-09-29
KR20230159363A (ko) 2023-11-21
ECSP23054131A (es) 2023-09-29
EP4263534A1 (en) 2023-10-25
WO2022130304A1 (en) 2022-06-23
CN116685326A (zh) 2023-09-01
MX2023007218A (es) 2023-07-27
CA3202198A1 (en) 2022-06-23
JP2023554492A (ja) 2023-12-27
US20240059669A1 (en) 2024-02-22
CR20230261A (es) 2023-10-04
IL303738A (en) 2023-08-01
PE20231441A1 (es) 2023-09-14
DOP2023000126A (es) 2023-11-30
AU2021402415A1 (en) 2023-07-06
CL2023001753A1 (es) 2024-02-02

Similar Documents

Publication Publication Date Title
TW202241881A (zh) Cdk抑制劑之共晶體
JP6882299B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP6059723B2 (ja) ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
CN109414442B (zh) 一种化合物的液体制剂
TW202115059A (zh) Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
TWI698428B (zh) Mdm2抑制劑之製備方法及結晶型
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
TW201620896A (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
BR112014022789A2 (pt) formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
WO2021098859A1 (zh) 氮杂七元环类抑制剂及其制备方法和应用
TW201620912A (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
CA3018014A1 (en) Naphthyridines as integrin antagonists
KR20120113760A (ko) 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN102648194B (zh) 化合物、其某些新形式、其药物组合物以及制备和使用方法
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
CN120322431A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
WO2017128036A1 (zh) 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
WO2020172906A1 (zh) 一种新型pan-RAF激酶抑制剂及其用途
CN108473492A (zh) 用于医学应用的3-(1,2,4-三唑并[4,3-a]吡啶-3-基乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型结晶盐形式
HK40099717A (zh) Cdk抑制剂的共晶体
EA050691B1 (ru) Сокристалл ингибитора cdk
CN116917273A (zh) 作为dnmt1抑制剂的经取代的吡啶
WO2022143695A1 (zh) 磺酰胺类抑制剂及其制备方法和应用
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途